Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 To 10.0 ng/ml

Journal of Urology

Volumn 170, Issue 3, 2003, Pages 723-726

  Khan, Masood A ^b   Partin, Alan W ^b   Rittenhouse, Harry G ^b   Mikolajczyk, Stephen D ^b   Sokoll, Lori J ^b   Chan, Daniel W ^b   Veltri, Robert W ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Adenocarcinoma; Prostate; Prostate specific antigen

Indexed keywords

ISOPROTEIN; PRO PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN DETECTION; ANTIGEN SPECIFICITY; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; MOLECULAR BIOLOGY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NONPARAMETRIC TEST; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; REFERENCE VALUE; ROC CURVE; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 0042738930     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000086940.10392.93     Document Type: Article

References (20)

1. Catalona, W. J., Richie, J. P., Ahmann, F. R., Hudson, M. A., Scardino, P. T., Flanigan, R. C. et al: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol, 151: 1283, 1994
2. Oesterling, J. E., Jacobsen, S. J., Chute, C. G., Guess, H. A., Girman, C. J., Panser, L. A. et al: Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA, 270: 860, 1993
3. Seaman, E., Whang, M., Olsson, C. A., Katz, A., Cooner, W. H. and Benson, M. C.: PSA density (PSAD). Role in patient evaluation and management. Urol Clin North Am, 20: 653, 1993
4. Catalona, W. J., Smith, D. S., Wolfert, R. L., Wang, T. J., Rittenhouse, H. G., Ratliff, T. L. et al: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA, 274: 1214, 1995
5. Brawer, M. K., Cheli, C. D., Neaman, I. E., Goldblatt, J., Smith, C., Schwartz, M. K. et al: Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer, J Urol, 163: 1476, 2000
6. Veltri, R. W., Miller, M. C., O'dowd, G. J. and Partin, A. W.: Impact of age on total and complexed prostate-specific antigen cut-offs in a contemporary referral series of men with prostate cancer. Urology, suppl., 60: 47, 2002
7. Mikolajczyk, S. D., Marks, L. S., Partin, A. W. and Rittenhouse, H. G.: Free prostate-specific antigen in serum is becoming more complex. Urology, 59: 797, 2002
8. Kumar, A., Mikolajczyk, S. D., Goel, A. S., Millar, L. S. and Saedi, M. S.: Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res, 57: 3111, 1997
9. Mikolajczyk, S. D., Millar, L. S., Wang, T. J., Rittenhouse, H. G., Wolfert, R. L., Marks, L. S. et al: "BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology, 55: 41, 2000
10. Mikolajczyk, S. D., Marker, K. M., Miller, L. S., Kumar, A., Saedi, M. S., Payne, J. K. et al: A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res, 61: 6958, 2001
11. Peter, J., Unverzagt, C., Krogh, T. N., Vorm, O. and Hoesel, W.: Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry. Cancer Res, 61: 957, 2001
12. Sokoll, L. J., Chan, D. W., Mikolajczyk, S. D., Rittenhouse, H. G., Evans, C. L., Linton, H. J. et al: Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis. Urology, 61: 274, 2003
13. Lilja, H., Christensson, A., Dahlen, U., Matikainen, M. T., Nilsson, O., Pettersson, K. et al: Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem, 37: 1618, 1991
14. Stenman, U. H., Leinonen, J., Alfthan, H., Rannikko, S., Tuhkanen, K. and Alfthan, O.: A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostate cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res, 51: 222, 1991
15. Veltri, R. W. and Miller, M. C.: Free/total PSA ratio improves differentiation of benign and malignant disease of the prostate: critical analysis of two different test populations. Urology, 53: 736, 1999
16. Catalona, W. J., Southwick, P. C., Slawin, K. M., Partin, A. W., Brawer, M. K., Flanigan, R. C. et al: Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology, 56: 255, 2000
17. Khan, A. R. and James, M. N.: Molecular mechanisms for the conversion of zymogens to active proteolytic enzymes. Protein Sci, 7: 815, 1998
18. Mikolajczyk, S. D., Millar, L. S., Wang, T. J., Rittenhouse, H. G., Marks, L. S., Song, W. et al: A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res, 60: 756, 2000
19. Carter, H. B., Walsh, P. C., Landis, P. and Epstein, J. I.: Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol, 167: 1231, 2002
20. Ellison, L., Cheli, C. D., Bright, S., Veltri, R. W. and Partin, A. W.: Cost-benefit analysis of total, free/total, and complexed prostate-specific antigen for prostate cancer screening. Urology, suppl., 60: 42, 2002